AL 58805
Alternative Names: AL-58805Latest Information Update: 09 Apr 2024
At a glance
- Originator Advenchen Laboratories
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 03 Apr 2024 Preclinical development of AL 58805 is going on in USA(Advenchen Laboratories pipeline, April 2024)
- 03 Apr 2024 Phase-I development of AL 58805 is going on in China (Advenchen Laboratories pipeline, April 2024)
- 09 Sep 2020 Phase-I clinical trials in Cancer in China (unspecified route), prior to September 2020 (Advenchen Laboratories pipeline, September 2020)